Get started
I-MABI-MABI-MAB

I-MAB

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

IMAB chart


Full chart

IMAB upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪65.29 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.7101 USD
Net income (FY)
‪−56.59 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪78.41 M‬
Beta (1Y)
1.39

About I-MAB


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Xi-Yong Fu
Website
i-mabbiopharma.com
Headquarters
Rockville
Founded
2016
FIGI
BBG00QQ8DFK6
I-Mab operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zang on June 30, 2016 and is headquartered in Rockville, MD.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

IMAB news



Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as IMAB.